ENVB

ENVB

USD

Enveric Biosciences Inc. Common Stock

$5.700-0.400 (-6.557%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$6.100

Hoch

$6.645

Tief

$5.520

Volumen

0.25M

Unternehmensfundamentaldaten

Marktkapitalisierung

3.0M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.07M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $5.52Aktuell $5.700Hoch $1444.5

Ähnliche Nachrichten

BusinessWire

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric expects to file Investigational New Drug application for EB-003 in early 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic

Mehr anzeigen
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
BusinessWire

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that

Mehr anzeigen
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
BusinessWire

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or

Mehr anzeigen
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
BusinessWire

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or

Mehr anzeigen
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications